Acorda Therapeutics Inc (ACORQ)
Market Cap | 821.03K |
Revenue (ttm) | 117.63M |
Net Income (ttm) | -252.85M |
Shares Out | 1.24M |
EPS (ttm) | -203.57 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 63,391 |
Open | 0.510 |
Previous Close | 0.520 |
Day's Range | 0.400 - 0.650 |
52-Week Range | n/a |
Beta | 1.46 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | n/a |
About ACORQ
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. f... [Read more]
Full Company ProfileFinancial Performance
In 2023, ACORQ's revenue was $117.63 million, a decrease of -0.79% compared to the previous year's $118.57 million. Losses were -$252.85 million, 283.6% more than in 2022.
Financial numbers in USD Financial StatementsNews
Acorda Therapeutics Announces Delisting from Nasdaq
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Delisting from Nasdaq.
Acorda Therapeutics Announces Nasdaq Delisting Notification
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Nasdaq Delisting Notification.
Acorda Therapeutics shares sink nearly 40% after bankruptcy filing
Shares of Acorda Therapeutics ACOR, +1.96% fell late Monday after the company said it had filed for bankruptcy protection.
Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement.
Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Cancels Q4 and Year End 2023 Earnings Conference Call Scheduled for April 1, 2024.
Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Fourth Quarter/Year End 2023 Update: Webcast/Conference Call Scheduled for April 1, 2024.
Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025.
Acorda Therapeutics Reports Third Quarter 2023 Financial Results
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Third Quarter 2023 Financial Results.
Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023.
Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA®.
Acorda Therapeutics Reports Second Quarter 2023 Financial Results
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports Second Quarter 2023 Financial Results.
Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The Fighters™”
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Launch of New INBRIJA® Campaign: “For The FightersTM”.
Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Second Quarter 2023 Update: Webcast/Conference Call Scheduled for August 8, 2023.
Tom Burns Elected to the Acorda Therapeutics Board of Directors
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Tom Burns Elected to the Acorda Therapeutics Board of Directors.
Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement.
Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Regains Compliance with Nadaq Minimum Bid Price Requirement.
Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Announces Completion of 1-for-20 Reverse Stock Split.
Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Conduct 1-for-20 Reverse Stock Split.
Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics CEO Ron Cohen, M.D., to Hold Virtual Company Presentation and Q&A.
Acorda Therapeutics Reports First Quarter 2023 Financial Results
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics Reports First Quarter 2023 Financial Results.
Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Make June 2023 $6.2 Million Interest Payment on Secured Debt in Cash.
Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics and Chance Pharmaceuticals Announce Agreement to Commercialize INBRIJA® in China.
Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda First Quarter 2023 Update: Webcast/Conference Call Scheduled for May 11, 2023.
Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting
PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics to Present INBRIJA® Data at the American Academy of Neurology Annual Meeting.
Acorda Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Acorda Therapeutics, Inc. (Nasdaq: ACOR) today reported its financial results for the fourth quarter and full year ended December 31, 2022.